Traditional factors
History, blood pressure, diabetes, obesity, cholesterol and other clinical data remain at the center of the evaluation.
Cardiovascular prevention
CardioRisk: cardiovascular risk assessment.
CardioRisk combines history, clinical factors, laboratory tests and genetic variants to make risk assessment more individual and support the conversation with your doctor.
- Accepted samples
- Peripheral blood, Buccal swab (preferred), Extracted DNA
- Turnaround time and when it starts
- 20 calendar days, after acceptance of the sample
- Medical order
- Required. View requirements and limitations.
Personalized prevention
An integrated reading of risk.
Cardiovascular risk results from the interaction between genetics, age, family history, clinical conditions and habits. CardioRisk organizes this information to support an individualized monitoring plan.
Inherited predisposition
Monogenic variants and risk scores can add information about cardiovascular predispositions.
Contextualized result
The report brings together the relevant findings for discussion with the doctor, without replacing the clinical assessment.
Clinical indication
When to consider CardioRisk?
The indication must consider age, history, previous tests and the clinical question. The result should not be interpreted in isolation.
01
Adults between 40 and 74 years old
Range in which the risk tends to increase, especially when there is hypertension, diabetes, obesity or other comorbidities.
02
Relevant family history
Heart attack, stroke, arrhythmias, cardiomyopathies or other cardiovascular diseases in close relatives.
03
Heart condition without defined cause
Symptoms or changes in which a hereditary condition may contribute to the diagnostic investigation.
04
Multiple risk factors
Complex situations where integrating genetics and clinical data can refine stratification.
05
Family planning
Families who want to understand the possibility of passing on hereditary heart conditions.
06
Cardiovascular research
Clinical projects that investigate the genetic contribution to cardiovascular disease, according to a specific protocol.
Risk stratification
Genetic information can anticipate risk identification.
In a study with more than 40,000 NHS participants, combining a polygenic score with QRISK2 increased the identification of people aged 40 to 54 classified as having high cardiovascular risk. The individual benefit depends on the clinical context and the population analyzed.
26%
Proportion identified by the clinical method presented in the study.
38,4%
Proportion identified after incorporating the polygenic score.
47,7%
Relative increase in identification in the analyzed section; does not represent an individual reduction in events.
Follow-up after your results
Infinity VUS
All NeoGenomica tests include Infinity VUS to follow reported variants of uncertain significance. When a relevant reclassification is confirmed after specialist review, the doctor is notified and the report may be updated.
Understand results and Infinity VUSTesting process
From assessment to care plan.
An integrated flow to combine clinical, laboratory and genetic data.
-
01
Clinical assessment
Forms gather history, risk factors and laboratory results.
-
02
Sample collection
Mouth swab or blood, as directed by the team.
-
03
Integrated analytics
Clinical, laboratory and genetic data are evaluated together.
-
04
Report and guidance
The result supports medical discussion and follow-up planning.
Interpretation
An organized result for the query.
The report presents the main findings, lists the risk categories assessed and offers support for medical monitoring.
- Summary of relevant clinical and genetic findings.
- Analysis by category of cardiovascular disease.
- Recommendations for discussion with the doctor and, when applicable, family members.
Frequently asked questions
Before ordering.
Does CardioRisk replace cardiological evaluation?+
No. The test adds genetic information to the evaluation of clinical and laboratory factors. Interpretation and any care decisions should be made with the doctor.
What can the result show?+
The report can bring together monogenic predispositions, risk scores and their relationship with clinical information, depending on the contracted scope and the quality of the data received.
How is sample collection done?+
The sample can be a mouth swab or blood. The team informs you of the appropriate material and guides sample collection and shipping.
Does a high genetic risk mean I will have the disease?+
Not necessarily. Predisposition is not diagnosis. Age, habits, other conditions and treatments also influence risk and need to be considered.
Could the result be relevant to family members?+
Hereditary findings may justify evaluation of family members. When this occurs, the report will guide the discussion with the assistant team.
Next step
Bring more context to your cardiovascular prevention.
Talk to the team to understand the scope, sample collection and how to integrate the result into medical monitoring.
Test information
Technical details for CardioRisk
Method, scope, requirements and limitations
Genetic assessment applied to cardiovascular risk and personalized prevention.
- Applications
- Personalized prevention, Cardiovascular risk
- Accepted samples
- Peripheral blood, Buccal swab (preferred), Extracted DNA
- Estimated turnaround time
- 20 calendar days, after acceptance of the sample
- Methodology
- Integrated assessment of clinical, laboratory and genetic data.
- Analytical scope
- Traditional factors, monogenic variants and cardiovascular risk scores, contextualized in the report.
- Medical order
- Required
Requirements
History, risk factors and laboratory results; the indication considers age, history, previous tests and clinical question.
Limitations
The result should not be interpreted in isolation and does not replace clinical assessment.
Additional information
Genetics adds a layer to traditional factors; age, history, clinical conditions and habits remain central.
